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1634Objective: Left ventricular assist device support produces a bleeding diathesis. Evidence suggests a major role
for von Willebrand factor (vWF). We examined vWF metabolism in a preclinical model of short-term
mechanical circulatory support.
Methods: In 25 calves (weight, 80-110 kg), the inflow/outflow graft of the Symphony Heart Assist System was
sewn end-to-side to the carotid artery. Supportwas initiated (acute, n¼ 4; 1week, n¼ 16; 2weeks, n¼ 5).Acutely,
carotid artery pressure and flow were measured to evaluate the hemodynamic changes near the anastomosis. At
baseline and after 2 weeks of support, platelet aggregometry with adenosine 50-diphosphate, collagen, and
ristocetin was performed. Gel electrophoresis and wet immunoblotting qualitatively evaluated vWF multimers
and quantified plasma ADAMTS-13, the vWF-cleaving protease. Carotid arterial rings near the anastomosis
were studied with immunohistochemical staining for ADAMTS-13 and were cultured to quantify endothelial
ADAMTS-13 production. Fluorescent resonance energy transfer was used to evaluate the enzymatic activity of
ADAMTS-13 in the plasma and in supernatant from cultured carotid arterial rings. Plasma interleukin-6, which
inhibits ADAMTS-13 activity, was measured using an enzyme-linked immunosorbent assay.
Results: During support, statistically significant (P<.05) changes in the carotid endothelium arterial hemody-
namics were observed. The highest molecular weight vWFmultimers were absent, and the vWF-ristocetin platelet
aggregation pathwaywas significantly impaired. Amodest but significant increase in plasmaADAMTS-13 protein
and activity was observed. ADAMTS-13 decreased significantly in the carotid near the anastomosis but increased
significantly in supernatant from cultured carotid arterial rings. The plasma interleukin-6 levels did not change
significantly.
Conclusions: Hemodynamic activation of vWF and increased plasma ADAMTS-13 activity may have reduced
high-molecular-weight vWFmultimers and thereby impaired the vWF-platelet aggregation pathway. Additional
delineation of these pathways may improve management of left ventricular assist device-associated bleeding.
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The Journal of Thoracic and Cardiovascular SurRecent reports have documented impairment of the von
Willebrand factor (vWF) pathway1-11 and nonsurgical
bleeding12 during mechanical circulatory support. In these
studies, acquired von Willebrand syndrome developed in
patients with continuous-flow1-11 and pulsatile-flow1,4,5,9
left ventricular assist devices (LVADs). The absence of
high-molecular-weight vWF multimers contributed to a
bleeding diathesis in these patients.
Limited data exist to explain the mechanisms of acquired
vonWillebrand syndrome in patients with an LVAD. During
in vitro LVAD support in a mock circulatory loop, degrada-
tion of vWF occurred rapidly as a result of multiple
mechanisms that occurred simultaneously.13 Shear-
induced mechanical demolition, in which vWF monomer
subunits were broken off from vWF multimers, may have
played a significant role. In parallel, ADAMTS-13, the
vWF protease, constitutively cleaved vWF into fragments
in the plasma.
To investigate the potential pathophysiologicmechanisms
of acquired vonWillebrand syndromeduringmechanical cir-
culatory support in vivo, we implanted the Symphony Heartgery c May 2014
Abbreviations and Acronyms
ADP ¼ adenosine 50-diphosphate
FRET ¼ fluorescent resonance energy transfer
IL ¼ interleukin
LVAD ¼ left ventricular assist device
PRP ¼ platelet-rich plasma
SDS ¼ sodium dodecyl sulfate
vWF ¼ von Willebrand factor
Bartoli et al Evolving Technology/Basic ScienceAssist System14 (Abiomed, Inc, Danvers, Mass), a novel
partial-support counterpulsatile LVAD, in calves. Platelet
aggregation, vWFmultimers, ADAMTS-13, and interleukin
(IL)-6, which inhibits ADAMTS-13, were examined.E
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The present study was conducted in accordance with the National
Institutes of Health guidelines for the care and use of animals in research.
The Institutional Animal Care and Use Committee of the University of
Louisville (Louisville, Ky) approved all experimental procedures.
Study Overview
The Symphony Heart Assist System (Abiomed, Inc) is a 30-mL
displacement pump designed to deliver prolonged partial support in
ambulatory patients with heart failure (Figure 1, B and C). The pump is
implanted posterior to the pectoralis major muscle without entering the
chest. A modified Gore-Tex graft (W. L. Gore & Associates, Flagstaff,
Ariz) is sewn end-to-side to the subclavian artery. The patient’s electro-
cardiogram is continuously monitored, and an R-wave–sensing algorithm
controls filling and emptying of the pump. The Symphony fills during
native cardiac systole to reduce left ventricular afterload and ejects during
native cardiac diastole to augment the diastolic blood pressure. Improved
coronary and systemic blood flow occurs. By these mechanisms, the
myocardial oxygen supply/demand relationship improves,14 and end-
organ perfusion increases.
Aspects of the design, implantation strategy, support mechanism, and
control algorithm of the Symphony pump are unique. The Symphony is
designed with a valveless inflow/outflow cannula. A constant but shifting
vortex continuously ‘‘washes’’ the interior of the pump to prevent
thrombosis. Implantation (and explantation) with a simple subcutaneous
procedure does not require extracorporeal circulation, sternotomy, or
thoracotomy. The Symphony functions as a peripheral capacitance
chamber that does not influence the internal impedance of the aorta.
Adjustment of the timing of filling and ejection permit modest tradeoffs
between improved coronary flow and reduced left ventricular workload.
Consequently, subtle variations in the delivery of support may have
important utility for incremental patient management on an individualized
basis, especially during weaning of the device if explantation is indicated.
Importantly, the low manufacturing cost and cost of implantation of the
Symphony pump may expand the use of mechanical circulatory support
in underserved foreign markets. A clinical trial with the Symphony
pump is currently underway in Canada and France.15
We used 25 male calves (weight, 80-110 kg) to evaluate the Symphony
pump. The study was performed according to the Good Laboratory
Practices (GLP) guidelines to determine the preclinical safety of the
pump. The calves were supported acutely (n ¼ 4) or were provided unin-
terrupted support for 1 week (n ¼ 16) or 2 weeks (n ¼ 5) with the Sym-
phony pump.
The Symphony pump was implanted subcutaneously in the neck. An
anastomosis was performed between the pump graft and the carotid arteryThe Journal of Thoracic and Caras described below. This approach was chosen because of the similar size
(approximately 8-10 mm in diameter) of the bovine carotid artery and the
human subclavian artery and the similar distance (approximately 8-10 cm
in distance) from the anastomosis to the aortic valve in humans and cows.16
Experimental Design
Blood samples were collected at baseline before implantation of the
Symphony pump and after 1 or 2 weeks of support prior to euthanasia.
As such, each calf was its own control. Likewise, analysis of the carotid
artery harvested near the anastomosis of the pump and the contralateral
carotid artery enabled each calf to also be used as its own control.
Platelet aggregometry was performed on platelet-rich plasma (PRP,
n ¼ 14) to evaluate platelet aggregation pathways. Gel electrophoresis
and wet immunoblotting were performed to evaluate plasma vWF
multimers (n ¼ 14) and to quantify plasma ADAMTS-13 (n ¼ 14).
Immunohistochemical staining for ADAMTS-13 was performed on
carotid arterial rings near the anastomosis (n ¼ 8) to evaluate endothelial
ADAMTS-13. Later, carotid arterial rings were cultured in vitro to quantify
endothelial ADAMTS-13 production near the anastomosis (n ¼ 5).
Fluorescent resonance energy transfer (FRET) was used to evaluate plasma
ADAMTS-13 activity in the plasma (n ¼ 14) and in the supernatant from
cultured carotid arterial rings (n ¼ 5). An enzyme-linked immunosorbent
assay was performed to measure plasma IL-6 (n ¼ 14). In addition to the
histologic and molecular analyses, carotid artery hemodynamics
were measured acutely (n ¼ 4) to quantify the hemodynamic changes
associated with partial support using an end-to-side anastomosis to a
peripheral artery.
Surgical Preparation
The calves were anesthetized with 3% to 5% isoflurane and prepared
for sterile surgery. Permanent fluid-filled catheters were placed in the right
jugular vein for intravenous access and in the proximal right carotid
artery for arterial blood pressure monitoring. A left fifth intercostal space
minithoracotomy was performed to place screw-in epicardial electro-
cardiographic leads (Medtronic, Inc, Minneapolis, Minn).
The calf was repositioned, and a left neck incision was made. The
Symphony pump (30-mL stroke volume) was implanted in a subcutaneous
pocket (7 cm 3 7 cm 3 5 cm) in the anterior neck. The percutaneous
driveline was tunneled to the nape of the neck, externalized, and attached
to a pneumatic driver (iPulse, Abiomed, Inc). A modified 8-mm
Gore-Tex vascular graft (W. L. Gore & Associates) was sewn end-to-side
to the carotid artery and connected to the pump. Care was taken to
completely de-air the pump. Pump filling and emptying were triggered
by the electrocardiogram using R-wave recognition software. Device
emptying and filling were timed to produce diastolic augmentation and
afterload reduction, respectively.
In a subset of calves, carotid artery pressure and flow were measured
acutely. Transit-time ultrasonic flow probes (Transonic, Inc, Ithaca, NY)
were placed around the carotid artery proximally and distally to the
anastomosis. High-fidelity single-tip micromanometer catheters (Millar
Instruments, Inc, Houston, Tex) were placed directly into the carotid artery
proximal and distal to the anastomosis. The Symphony was operated in an
uninterrupted 1:1 support mode in which each ventricular systole resulted
in pump filling and each ventricular diastole-triggered pump ejection. He-
modynamics were recorded for 30-s epochs at baseline and for 30-s epochs
during 1:1 Symphony support.
Each calf wasmaintained on a daily dose of 75mg of clopidogrel, which
was started 1 day before surgery. Intraoperatively, the calves received
10,000 U of heparin before clamping the carotid artery to perform the
end-to-side graft anastomosis. After anastomosis completion and initiation
of device support, heparin was reversed with 100 mg of protamine. At 6
hours after surgery, a continuous heparin infusion was initiated and titrated
to maintain an activated clotting time of>200 s. Warfarin was initiated on
postoperative day 3 and titrated to maintain an international normalizeddiovascular Surgery c Volume 147, Number 5 1635
FIGURE 1. A, The anatomic configuration of the Symphony Heart Assist System is shown in cows. B and C, The anatomic configuration of the Symphony
Heart Assist System is shown in humans. In humans, the pump is sewn end-to-side to the subclavian artery. The pump fills during native cardiac systole to
reduce afterload and ejects during native cardiac diastole to augment diastolic blood pressure, increase coronary blood flow, and improve the myocardial
oxygen supply/demand relationship. C and D, In the segment of artery between the anastomosis and the aorta, blood flows antegrade during pump filling and
retrograde during pump ejection. Thus, the hemodynamic profile (pressure, flow, flow directionality, turbulence, shear stress) at the anastomosis is changed
significantly. D, At baseline, a normal profile of carotid arterial blood pressures and flow were present (left). During 1:1 support, in which each ventricular
systole triggered pump filling and each ventricular diastole triggered pump ejection, nonphysiologic pressures and flow were observed (middle). The aortic
pressure tracings demonstrated effective diastolic augmentation during 1:1 support (top right) and 1:2 support (bottom right). E and F, Blood flow was
quantified at baseline and during 1:1 support proximally and distally to the anastomosis. In the segment of vessel distal to the anastomosis, augmented
flow was observed during native cardiac diastole when the pump ejected. In the segment of vessel proximal to the anastomosis, augmented flow was
observed during native cardiac systole when the pump was filling. Complete flow reversal was observed in the artery proximal to the anastomosis during
pump ejection.
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therapeutic.
After recovery, chronic animals underwent uninterrupted support for 1 or
2 weeks. On completion of the planned duration of support, euthanasia was
induced with an intravenous bolus of Beuthanasia-D Special (1 mL/5 kg).
Hemodynamic Data Reduction and Analysis
Hemodynamic transducers were pre- and postcalibrated against known
physical standards to ensure measurement accuracy. High-fidelity hemody-
namic waveforms were signal conditioned (10003 gain and 60-Hz
low-pass filter) and analog-to-digital converted at a sampling rate of 400
Hz for digital analysis using our GLP-compliant data acquisition system.17
To determine the hemodynamic values at baseline and during
Symphony support, the carotid artery flow and pressure waveforms were
recorded to derive the mean, peak antegrade, and peak retrograde carotid
artery flow and systolic and diastolic arterial pressures proximal and distal1636 The Journal of Thoracic and Cardiovascular Surto the anastomosis. The hemodynamic values were calculated on a beat-to-
beat basis for each 30-s data epoch using the Hemodynamic Evaluation and
Assessment Research Tool program18 developed in MATLAB (Math-
works, Inc, Natick, Mass). All analyzed beats in each data set (approxi-
mately 30-40 beats/30-s data set) were averaged to obtain a single
representative mean value.Blood Collection
Whole blood (approximately 8 mL) was collected at baseline and
prior to termination after the planned duration of support. From each
sample, a complete blood count was measured to obtain the platelet count,
and PRP was prepared for platelet aggregation studies. Platelet-poor
plasma was snap-frozen with liquid nitrogen for wet immunoblotting of
plasma vWF and ADAMTS-13 and determination of ADAMTS-13 activity
using FRET.gery c May 2014
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Fresh whole bloodwas anticoagulated in 4.5mL buffered sodium citrate
blood tubes (BD Biosciences, Franklin Lakes, NJ). The blood was trans-
ferred to plastic cuvettes and centrifuged at 210g for 12 minutes at 22C.
The supernatant PRP fraction was aspirated into a fresh tube. The
remaining bloodwas centrifuged again at 1000g for 15minutes to sediment
platelets. The supernatant platelet-poor plasma was transferred to a fresh
tube and snap-frozen for subsequent immunoblotting and FRET analysis.
Platelet aggregation was measured with a 4-channel platelet aggregom-
eter (Chrono-Log Corp, Havertown, Pa).19 Each PRP sample (approxi-
mately 2.5 3 108 platelets/mL) was incubated with 2 mM calcium at
37C with continuous stirring at 1000 rpm. PRP samples were stimulated
to aggregate separately with adenosine 50-diphosphate (ADP) (10 mM),
collagen (10 mg/mL), and ristocetin (4 mg/mL). Aggregation wasmeasured
at a fixed interval of 10 minutes for ADP and ristocetin and 20 minutes for
collagen. The percentage of aggregation was measured as absorbance.
Aggregated PRP was fixed in 10% buffered formalin. Platelets were
stained with fluorescein isothiocyanate (FITC)–conjugated wheatgerm
agglutinin for sialic acid in platelet membranes and counterstained with
DAPI20 to confirm that the aggregates were composed of platelets alone
and not nucleated cells.
vWFAnalysis
The relative size of plasma vWF multimers was analyzed by standard
immunoblotting techniques.13 Plasma samples at baseline and after
Symphony support were each combined 1:10 with loading buffer
(10 mM Tris HCl, 1 mM ethylenediaminetetra-acetic acid, 2% sodium
dodecyl sulfate [SDS], 8 M urea, and bromophenyl blue; pH 8.0). The
samples were heated in a 60C water bath for 20 minutes and loaded
into 1.8% agarose-SDS gels (7 3 8.3 cm 3 1.5 mm, 1% SDS, 0.375 M
Tris HCl) and underwent electrophoresis at 40 V for 4.5 to 5 hours at
4C in Tris buffer (0.05 M, 0.384 M glycine, 0.1% SDS). Proteins were
transferred at 30 V for 16 hours to an Immobilon-P polyvinylidene
diflouride membrane (Millipore, Billerica, Mass) by wet electroblotting
in phosphate buffer (0.2 M phosphate, 0.04% SDS, pH 7.4). The blots
were incubated with rabbit anti-human vWF primary antibody (1/500;
Dako, Inc, Carpinteria, Calif) overnight at 4C and goat anti-rabbit IgG
horseradish peroxidase-conjugated secondary antibody (1/3000; Cell
Signaling, Inc, Danvers, Mass) for 1 hour. The blots were developed
with ECL Plus Western blotting detection reagents (GE Healthcare, Inc,
Piscataway, NJ), scanned, and imaged with a Typhoon 9400 Variable
Mode Imager (GE Healthcare, Inc).
Analysis of ADAMTS-13
Plasma ADAMTS-13 levels were analyzed using standard immunoblot-
ting techniques. Plasma samples at baseline and after Symphony support
were each diluted 1:5, 1:10, 1:20, and 1:40 with loading buffer (10 mM
Tris HCl, 1 mM ethylenediaminetetra-acetic acid, 2% SDS, 8 M urea, and
bromophenyl blue; pH 8.0). The samples were heated in a 95C water bath
for 5 minutes, loaded into 7% polyacrylamide-SDS gels (1.5-mm thick,
10% SDS, 0.5 M Tris, 10% ammonium persulfate and 10 mL TEMED),
and underwent electrophoresis at 60 V for 7.5 hours at 4C in a Tris running
buffer (0.025 M, 0.192 M glycine, 0.1% SDS; pH 8.4). The proteins were
transferred at 30V for 12 hours to an Immobilon-P polyvinylidene diflouride
(Millipore) membrane by wet electroblotting in Tris buffer (0.025 M, 0.192
M glycine, 0.04% SDS, 20%methanol; pH 8.3). Blots were incubated with
rabbit anti-human ADAMTS-13 primary antibody (1/1000; Abcam Inc,
Cambridge, Mass) overnight at 4C and goat anti-rabbit IgG horseradish
peroxidase-conjugated secondary antibody (1/3000; Cell Signaling, Inc)
for 1 hour. Blots were developed with ECL Plus Western blotting detection
reagents (GE Healthcare, Inc), scanned, and imaged with a Typhoon 9400
Variable Mode Imager (GE Healthcare, Inc).
ADAMTS-13 activity in plasma was determined with a commercial
FRET kit (American Diagnostica, Inc, Stamford, Conn) according toThe Journal of Thoracic and Carmanufacturer’s instructions. In brief, Alexa-fluorochrome–conjugated
recombinant vWF was added to the plasma samples. At 37C, proteolytic
cleavage of the vWF-Alexa substrate uncoupled Alexa fluorochromes and
resulted in an increase in fluorescence. The increase in fluorescence over
time (maximal volume) was measured with a spectrofluorometer. A
standard curve was constructed with a known plasma concentration of
ADAMTS-13. ADAMTS-13 activity was determined by interpolation of
the maximal volume values from the standard curve.
The total protein content was determined in plasma and carotid arterial-
ring culture supernatant with a bicinchoninic acid colorometric assay. In
brief, the samples were diluted 1:50 in phosphate-buffered saline. Standard
bicinchoninic acid colorometric protein assay reagents (PierceChemicalCo,
Rockford, Ill) and a 96-well microplate reader (Spectramax 190, Molecular
Devices, Sunnyvale, Calif) were used. Sample protein concentrations were
interpolated from a standard curve generated with known concentrations
of bovine serum albumin (Fisher Scientific, Hampton, NH).
Immunohistochemistry
At termination, arterial cross sections were harvested near the
anastomosis and from the contralateral (control) carotid artery. The tissue
sections were embedded in paraffin, sectioned at 4 mm, deparaffinized, and
rehydrated. Standard antigen retrieval was performed. The sections were
permeabilized (0.05% Saponin), blocked (2% bovine serum albumin
and 2% goat serum in phosphate-buffered saline), incubated with rabbit
anti-human ADAMTS-13 primary antibody (1/500; Abcam, Inc) for 24
hours at 4C and FITC-conjugated goat anti-rabbit IgG secondary antibody
(1/200; Invitrogen, Carlsbad, Calif) for 1 hour at room temperature. The
stained sections were mounted with DAPI. Images were acquired using ep-
ifluorescence microscopy (Nikon TE2000; Nikon Corp, Tokyo, Japan).
In Vitro Carotid Arterial Ring Culture
At termination, with sterile technique, carotid artery from within 2 cm
of the anastomosis (n ¼ 5) toward the heart and the contralateral (control)
carotid artery were harvested. Carotid arterial rings (2 mm) were
embedded in Matrigel (BD Biosciences, Bedford, Mass) and mixed 1:1
with endothelial media (Dulbecco’s modified Eagles medium, 10% fetal
bovine serum, 1% penicillin/streptomycin, 150 mg/mL vascular
endothelial growth factor, 60 U/mL heparin). After 36 hours of growth,
the supernatant was snap-frozen in liquid nitrogen. Supernatant
ADAMTS-13 protein and activity were determined with immunoblotting
and FRET, as previously described.Enzyme-Linked Immunosorbent Assay
The plasma IL-6 levels were measured with a sandwich enzyme-linked
immunosorbent assay IL-6 kit (Pierce Biotechnology) according to the
manufacturer’s instructions. In brief, the microtiter plate was precoated
with monoclonal antibody specific to bovine IL-6. The plasma samples
were incubated in the coated wells overnight at 4C. The wells were
emptied, washed, and incubated for 1 hour at room temperature with a
biotin-conjugated polyclonal antibody preparation specific for IL-6.
Microplate wells were aspirated and washed 3 times before incubation
with a solution of avidin-conjugated horseradish peroxidase for 30 minutes
at room temperature. The washing was repeated. Tetramethylbenzidine
was added, and the reaction was incubated for 20 minutes. The reaction
was stopped with 1 M H2S04, and the signal was measured using a
colorimetric microplate reader (Synergy Mx Microplate Reader; Biotek,
Winooski, Vt) at 450 nm.Statistical Analysis
GraphPad, version 5.00 (Prism, GraphPad Software, Inc, La Jolla, Calif)
was used to perform the statistical analyses and plot data. Paired Student’s
t tests were used to compare the baseline and Symphony hemodynamicdiovascular Surgery c Volume 147, Number 5 1637
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tochemistry, plasma and cultured carotid arterial-ring supernatant
ADAMTS-13 activity, and plasma IL-6 levels. P<.05 (95% confidence)
was considered statistically significant. All data are presented as the
mean  standard error.RESULTS
Hemodynamics
The Symphony pump significantly altered the profile of
carotid artery hemodynamics (Figure 1). Carotid arterial
blood pressure changed from approximately 90/50 mm
Hg at baseline to 200/15 mm Hg during Symphony support
(Figure 1, D). Blood pressure values were similar proximal
and distal to the anastomosis. During ejection of the pump
during native cardiac diastole, approximately 33% of the
blood volume flowed cephalad through the distal carotid
artery. In contrast, 67% of the ejected blood volume
flowed retrograde through the proximal carotid artery
into the ascending aorta. Diastolic augmentation and
afterload reduction were achieved (Figure 1, D, right
panels). As previously reported, the Symphony pump
augments cardiac output and coronary blood flow and
reduces the left ventricular peak systolic pressure,
left ventricular external work, and myocardial oxygen
consumption.14,21-23
Proximal to the anastomosis, the peak antegrade blood
flow increased from a baseline flow of 1.4  0.3 to 4.3 
0.3 L/min during pump filling (P<.001; Figure 1, D and
F). The peak flow during pump ejection reversed completely
from an antegrade flow of 0.3  0.1 L/min to a retrograde
flow of 4.2  0.4 L/min (P< .001; Figure 1, D and F).
Flow reversal in the proximal carotid artery during diastole
resulted in antegrade flow augmentation into the aorta.
Distal to the anastomosis, the peak antegrade blood flow
increased from a baseline value of 1.1 0.1 L/min to 2.2
0.2 L/min during pump ejection (P ¼ .01; Figure 1, D and
E). Flow reversal did not occur in the distal carotid artery.Platelet Aggregation
After 7 days of Symphony support, platelet aggregationwith
ADP and collagen were unchanged. However, ristocetin-
mediated platelet aggregation through the vWF pathway was
significantly impaired (Figure 2,A-E). The amplitude of aggre-
gation decreased from 20% 4% at baseline to 14% 2%
after 1 week of Symphony support (P<.01). The slope of ag-
gregation decreased from 41% 4%/min to 30% 4%/min
(P<.05). Total platelet aggregation, as determined by the area
under the aggregation curve, decreased from 335%  20%/
min to 257%  28%/min (P< .001). The platelet number
from the complete blood count did not change significantly
from 251,000  19,000 platelets/mL at baseline to 258,000
 17,000 platelets/mL after Symphony support.
Morphologic differences existed between the platelet
aggregation curves at baseline and during Symphony1638 The Journal of Thoracic and Cardiovascular Sursupport (Figure 2, D). The baseline curves demonstrated a
biphasic aggregation pattern in which the initial robust
phase was followed by a smaller secondary phase of
aggregation. After peak aggregation, the aggregates were
stable and did not dissociate. In contrast, after Symphony
support, a biphasic response was absent, and the aggregates
spontaneously dissociated at a slow rate. Similarly,
after Symphony support, the ristocetin-induced platelet
aggregates were smaller and less numerous than the
aggregates at baseline (Figure 2, E).
Plasma vWF Immunoblotting
In 11 of 14 calves, wet immunoblotting demonstrated a
modest reduction in the high-molecular-weight vWF
multimers (Figure 2, F). A shift toward greater numbers of
mid- and low-molecular-weight vWFmultimerswas evident.
Plasma ADAMTS-13 Protein and Activity
In 10 of 14 calves, wet immunoblotting demonstrated an
increase in plasma ADAMTS-13 protein (Figure 3, A and
B). In 11 of 14 animals, the plasma ADAMTS-13 activity
increased. ADAMTS-13 activity after Symphony support
increased by 24.7 10.1 ng/mL (P<.05; Figure 3,C). Total
plasma protein was not different from baseline after Sym-
phony support.
Carotid Artery ADAMTS-13 Immunohistochemistry
The carotid artery endothelium near the anastomosis
exhibited decreased intracellular ADAMTS-13 levels
(Figure 4). The staining area was 23.5% 0.4% in the con-
trol carotid artery and 22.6% 0.5% near the anastomosis
(P ¼ .07). The staining intensity was 7.1  0.3 arbitrary
units in the control carotid artery and 6.1  0.3 arbitrary
units near the anastomosis (P<.05; Figure 4, A-H).
Cultured Carotid Artery ADAMTS-13 Activity
In all cultured carotid arteries, wet immunoblotting of the
supernatant demonstrated an increase in plasma ADAMTS-
13 protein and activity (Figure 5). ADAMTS-13 activity
was 39.7%  10.7% greater in the supernatant from the
carotid artery near the anastomosis compared with that in
the control carotid artery (P<.05; Figure 5, C). The total
supernatant protein was not different between the control
carotid arteries and carotid arteries near the anastomosis.
Plasma IL-6
At baseline, the plasma IL-6 was 1.04  0.74 ng/mL.
After 1 week of Symphony support, the plasma IL-6 was
0.89  0.55 ng/mL. This change was not statistically
significant (P ¼ .49).
DISCUSSION
Our findings suggest potential in vivo mechanistic path-
ways of vWF degradation during mechanical circulatorygery c May 2014
FIGURE 2. A-C, Platelet aggregometry with adenosine 50-diphosphate (ADP), collagen, and ristocetin demonstrated impaired aggregation through the
ristocetin-von Willebrand factor (vWF) pathway but not through the ADP or collagen pathways. D, Example platelet aggregation curves at baseline and
after Symphony support demonstrated impaired platelet aggregation through the vWF pathway. Morphologic differences existed between the platelet ag-
gregation curves. The baseline curve demonstrated a biphasic aggregation pattern in which the initial robust phase was followed by a smaller secondary
phase of aggregation. After peak aggregation, the aggregates were stable and did not dissociate. In contrast, after Symphony support, a biphasic response
was absent, and the aggregates spontaneously dissociated at a slow rate. E and F, Similarly, after Symphony support, the ristocetin-induced platelet aggre-
gates were smaller and less numerous than the aggregates at baseline. This finding may be related to the loss of the secondary phase of the biphasic platelet
aggregation response. G, After Symphony support, agarose-SDS gel electrophoresis and wet immunoblotting demonstrated a mild reduction of the highest
molecular-weight vWF multimers. A shift toward greater numbers of mid- and low-molecular-weight multimers was evident. B, Baseline; S, Symphony.
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hemodynamic profile near the anastomosis. After short-
term support in male calves, we observed: (1) impaired
platelet aggregation through the ristocetin-vWF pathway
but not the ADP or collagen pathways, (2) modestly
decreased high-molecular-weight plasma vWF multimers,
(3) modestly increased plasma ADAMTS-13, and (4)
increased ADAMTS-13 production by endothelium near
the anastomosis. IL-6, which inhibits ADAMTS-13 activity,
was unchanged and was unlikely to have played a role in
this process. We speculate that an altered hemodynamic
profile near the end-to-side anastomosis activated vWFThe Journal of Thoracic and Carfor enhanced cleavage by ADAMTS-13. In parallel,
increased endothelial production of ADAMTS-13 may
also have increased degradation of vWF. These mechanistic
pathways likely contribute to bleeding episodes in patients
with an LVAD.
Normal Mechanisms of vWF Degradation: Shear
Stress and ADAMTS-13
vWF, a 500- to 20,000-kD multimeric glycoprotein, is
constitutively manufactured by endothelial cells, circulates
in the plasma, and participates in primary hemostasis.24 At
sites of endothelial damage, turbulent blood flow anddiovascular Surgery c Volume 147, Number 5 1639
FIGURE 3. A, Wet immunoblotting demonstrated increased plasma
ADAMTS-13 protein after Symphony support. B, A bicinchoninic acid
colorometric assay demonstrated that the total plasma protein was not
different from baseline after Symphony support. C, ADAMTS-13
measured with fluorescent resonance energy transfer demonstrated
increased plasma ADAMTS-13 activity.
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Saltered shear stress cause vWF to undergo a conformational
change that facilitates vWF tethering to subendothelial
collagen and platelets by way of the glycoprotein 1b-V-IX
complex.25 Thus, a platelet plug covers the breached
endothelium. During this process, the highest molecular
weight vWF multimers are most susceptible to activation
by shear stress. However, shear-induced activation also
renders vWF more sensitive to proteolytic cleavage by
ADAMTS-13,26 the vWF-specific plasma metalloprotease.
As such, increased proteolytic cleavage of vWF can be
observed with an increase in shear-induced conformational
activation of vWF, an increase in ADAMTS-13, or both.
The basic mechanism of shear stress-induced activation
and degradation of vWF is well described.24 Clinical
correlates are well documented. For example, in patients
with critical aortic stenosis, shear stress through the stenotic
aortic annulus correlates with loss of high-molecular-
weight vWF multimers.27 Within hours of aortic valve
replacement surgery (and re-establishment of a normal
shear stress profile), high-molecular-weight vWF multi-
mers return. These findings highlight in humans the
mechanistic importance of shear stress-induced activation
and degradation of vWF.
Importantly, LVADs alter shear stress.28 The blood of a
patient with an LVAD is continuously exposed to supraphy-
siologic shear stresses, especially near the end-to-side1640 The Journal of Thoracic and Cardiovascular Suranastomosis. As a result, pathologic von Willebrand
degradation occurs in patients with continuous-flow1-11
and pulsatile-flow1,4,5,9 LVADs. It has been speculated
that acquired von Willebrand syndrome in LVAD patients
develops from the loss of high-molecular-weight vWF
due to mechanical destruction and proteolysis by
ADAMTS-13.29 Experimental evidence supports the
hypothesis that the major mechanism of vWF degradation
is mechanical destruction of vWF, with ADAMTS-13
playing a smaller role.13 Our current data further suggest
that ADAMTS-13 plays an ancillary role in this process.
Likely, shear-induced activation of vWF results in enhanced
vWF cleavage by ADAMTS-13.
ADAMTS-13 in the plasma and supernatant from the
cultured carotid artery rings near the anastomosis increased
modestly. These findings suggest that altered hemody-
namics near the end-to-side anastomosis activated endothe-
lium to increase production of ADAMTS-13. Evidence has
suggested that abnormal stresses stimulate endothelial
production30 and increased activity31 of ADAMTS-13.
Additionally, in a previous study in our model, circulatory
support triggered phenotypic changes in the endothelium
that resulted in a hypermetabolic state32 that may have
enhanced the production of ADAMTS-13. Therefore, we
speculate that non-physiologic hemodynamic loading
(increased pressure, increased flow, reverse flow, turbu-
lence, changes in shear stress) of endothelial cells near
the anastomosis increased production of ADAMTS-13.
There may have been multiple sources of increased
plasma ADAMTS-13 protein. ADAMTS-13 is produced
by hepatic stellate cells,33 endothelium,34 and platelets.35
In vitro mechanical circulatory support leads to platelet
activation and release of ADAMTS-13 from platelets
into the plasma.13 Therefore, the increase in plasma
ADAMTS-13 that we observed was likely from a
combination of activated platelets, hypermetabolic
endothelium near the anastomosis, and/or other sources.
Our results were not due to a change in the plasma IL-6
concentration. IL-6 inhibits ADAMTS-13 activity.36 As
such, changes in the inflammatory milieu caused by conti-
nuous blood contact with the interior artificial surface of
the pump may have influenced IL-6 levels and altered
ADAMTS-13 activity. However, the plasma IL-6 levels did
not change significantly andwere unlikely to have accounted
for the observed changes in ADAMTS-13 activity. Other
cytokines such as tumor necrosis factor-a and IL-10 do not
influence ADAMTS-13 activity36 and also likely did not in-
fluence vWF degradation. Together, these findings suggest
that acquired von Willebrand syndrome in patients with an
LVAD is independent of the systemic cytokine profile.
Clinical Implications
Multiple LVADs are clinically available or poised
for clinical trials.37 Each device produces a uniquegery c May 2014
FIGURE 4. ADAMTS-13 immunohistochemical staining demonstrated that endothelial cells contained reduced ADAMTS-13 near the anastomosis
compared with the contralateral (control) carotid arteries. A-H, The staining pattern of ADAMTS-13 in the control carotid artery was nearly uniform
and followed the contours of the endothelium. However, endothelial ADAMTS-13 near the anastomosis demonstrated diffuse staining that suggested active
mobilization of ADAMTS-13. A and E, Bright field images; B and F, FITC-conjugated ADAMTS-13 immunohistochemical staining; C and G, DAPI co-
nuclear stain; D and H, Overlay (403, white bar ¼ 100 mm); and I and J, Total staining area and staining intensity for ADAMTS-13 decreased in endo-
thelium near the anastomosis compared with the controls. Arb U, Arbitrary units.
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Shemodynamic profile with varying pulsatility, turbulence,
and shear stress, which serve as important biomechanical
activators of the clotting system.38 As such, certain device
types may trigger more pronounced activation and
degradation of vWF. For example, quantitative and
qualitative changes in shear stress may have important clin-
ical implications. Pulsatile-flow and continuous-flow
LVADs alter the shear stress profile differently. Pulsatile
pumps, such as the Symphony pump, alter the shear
stress gradient—rapid acceleration of blood during filling
and emptying of the pump produces bursts of high and
low shear. In contrast, during support with a continuous-
flow LVAD, native pulsatility is greatly diminished.39
As a result, continuous nonphysiologically high shear stress
persists, with little variation in the magnitude of the
shear stress.
Strong clinical evidence has shown that continuous-flow
LVADs produce more severe impairment of vWF and more
frequent bleeding episodes than pulsatile pumps.40 In light
of our data, we speculate that a high shear stress gradient
with a pulsatile-flow LVAD is less traumatic to vWF than
the constant high shear stress of a continuous-flow device.The Journal of Thoracic and CarOur vWF immunoblotting analysis demonstrated mild
reductions of the highest molecular weight vWF multimers
that were less dramatic than with continuous-flow
LVADs.1,3,5,6,8,9 Differences between pulsatile-flow and
continuous-flow LVAD activation and degradation of vWF
warrant additional investigation.
Interestingly, and in additional support of this point,
pathologic degradation of vWF has not been observed in
patients with a total artificial heart.1 Pulsatile blood flow
through a large end-to-end anastomosis may reproduce a
normal shear stress profile without the turbulence and shear
stress alterations that occur at an end-to-side anastomosis.
Hemodynamically, the end-to-end configuration of a total
artificial heart recapitulates normal cardiovascular anatomy
and produces physiologic flow patterns in series with the
circulation. In contrast, the end-to-side configuration of an
LVAD introduces a second circuit in parallel with the
circulation that causes flow channels to merge at the site
of the anastomosis. The effect is turbulence, high shear
stress, and high shear gradients at the end-to-side
anastomosis. Interestingly, vWF degradation occurs if the
device is connected end-to-side to the aorta or thediovascular Surgery c Volume 147, Number 5 1641
FIGURE 5. A, Wet immunoblotting demonstrated increased ADAMTS-
13 protein in supernatant from cultured carotid artery near the anastomosis
compared with the contralateral (control) carotid. B, A bicinchoninic acid
colorometric assay demonstrated that the total supernatant protein was not
different between the control carotid artery and the carotid artery near the
anastomosis. C, ADAMTS-13measured with fluorescent resonance energy
transfer demonstrated increased ADAMTS-13 activity in supernatant from
the carotid artery near the anastomosis compared with the controls.
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Ssubclavian artery.11 Therefore, we speculate that it is not the
site of the anastomosis, but rather the flow patterns at the
end-to-side anastomosis that may have important
implications for vWF degradation and the design of next
generation mechanical circulatory support devices. As
such, the end-to-side anastomosis should be considered as
a target for therapies.
The role of ADAMTS-13 in LVAD-induced acquired von
Willebrand syndrome is unclear. The limited existing data
are conflicting. In our study, with paired baseline controls,
we observed a small (24.7  10.1 ng/mL), but statistically,
significant increase in plasma ADAMTS-13 activity. The
clinical relevance of such a modest increase is unknown.
Clinical data have suggested that ADAMTS-13 does not
play a major role in acquired vonWillebrand syndrome dur-
ing mechanical circulatory support.3,4,8 However, these
studies were conducted in small subgroups of patients,
lacked controls, and it was not possible to make definitive
conclusions.13 In vitro data suggest that ADAMTS-13 plays
at least a minor role in LVAD-induced von Willebrand syn-
drome but was unlikely to be the dominant mechanism.13
The effects of mechanical circulatory support on
ADAMTS-13 protein and activity remain to be determined
in a large cohort of patients with appropriate paired1642 The Journal of Thoracic and Cardiovascular Surcontrols. In these studies, it will be necessary to measure
plasma ADAMTS-13 protein and activity, which may be
enhanced by shear stress.26
Mild impairment of prothrombotic pathways represents a
potential clinical benefit to prevent thromboembolism in
a patient with an LVAD. However, the optimal level
of vWF impairment is unknown. In humans,>50% vWF
deficiency is suggestive (not diagnostic) of von
Willebrand syndrome, but rarely causes bleeding.41 With
the Symphony pump, we observed a 30% functional
impairment of vWF-platelet aggregation, which may not
be of clinical concern. Similarly, the intra-aortic balloon
pump, a device which produces a similar hemodynamic
profile to the Symphony pump, has not been shown to
produce acquired von Willebrand syndrome, and bleeding
occurs in only 6% of intra-aortic balloon pump patients42
versus 27% to 75% of patients with an LVAD.2-4,7,8 An
ongoing clinical trial will determine the risk of
gastrointestinal bleeding with the Symphony pump. Less
vWF degradation compared to continuous-flow LVADs
may result in a lower incidence of bleeding in patients
with the Symphony pump.Study Limitations
Patients with heart failure typically develop endothelial
cell dysfunction, which was not present in the normal calves
used in the present study. Therefore, our results should be
interpreted in light of this limitation and should not be
extrapolated to human patients without caution.CONCLUSIONS
Our findings suggest in vivo mechanistic pathways of
vWF degradation during mechanical circulatory support.
Nonphysiologic hemodynamics near the anastomosis
increased local endothelial production of ADAMTS-13.
Hemodynamic activation of vWF and increased
plasma ADAMTS-13 may have contributed to reduced
high-molecular-weight vWF multimers and impairment of
the vWF-platelet aggregation pathway. Platelet aggregation
with ADP and collagen was unchanged, as were the
IL-6 levels. Further delineation of these pathways may be
of significance for the field of mechanical circulatory
support.
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